Purchase this article with an account.
Murilo Wendeborn Rodrigues, Rodrigo Jorge, Rubens C Siqueira, Jose A Cardillo; The Potential of Aflibercept as Monotherapy for the Treatment of Refractory or Unresponsive Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3974.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the immediate anatomical and functional result following single intravitreal injection of Aflibercept 2.0 mg in refractory eyes with wet age-related macular degeneration (AMD) previously medicate with other standard intravitreal injection drugs
Case series of 10 consecutive wet AMD eyes unresponsive or with persistent retinal fluid on optical coherence tomography (OCT) after at least 20 monthly intravitreous injections of either Ranibizumab or Bevacizumab were clinically assessed with best corrected visual acuity (BCVA) and OCT at 30, 60 and 90 days following a single Aflibercept injection
All eyes underwent a complete fluid resolution on OCT noticed as early as 30 days post-injection that maintained up to the 90<th> day post-treatment were observed in all cases. Five eyes improved one or more ETDRS line of vision and despite optimal anatomical response 5 eyes failed to demonstrate any visual acuity gain
Aflibercept appears to be an effective rescue monotherapy tool for the treatment of refractory or unresponsive neovascular Age-Related Macular Degeneration eyes and should be priority considerate instead of combined treatment with photodynamic therapy
This PDF is available to Subscribers Only